{"filing":{"accession_number":"0001493152-26-040930","cik":"0001904286","ticker":"MIRA","company_name":"MIRA PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-09-01","report_date":"2026-09-01","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226040930/form8-k.htm"},"events":[{"id":30796,"run_id":28237,"accession_number":"0001493152-26-040930","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"MIRA Pharmaceuticals disclosed positive preclinical toxicology results for MIRA-55, an investigational non-opioid drug candidate for inflammatory pain, and announced a targeting of IND submission in Q1 2027. This is a material operational/development milestone for a clinical-stage biotech company—the successful completion of dose-range finding studies and advancement toward regulatory submission represents a significant step in the drug development pipeline. While not a specific named event type (not earnings, M\u0026A, litigation, etc.), this is clearly an operational/strategic development milestone that would affect a reasonable investor's assessment of the company's progress and prospects.","company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","filing_date":"2026-09-01","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":33509,"accession_number":"0001493152-26-040930","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MIRA Pharmaceuticals disclosed positive preclinical toxicology results for MIRA-55, an investigational non-opioid drug candidate for inflammatory pain, and announced a targeting of IND submission in Q1 2027. This is a material operational/development milestone for a clinical-stage biotech company—the successful completion of dose-range finding studies and advancement toward regulatory submission represents a significant step in the drug development pipeline. While not a specific named event type (not earnings, M\u0026A, litigation, etc.), this is clearly an operational/strategic development milestone that would affect a reasonable investor's assessment of the company's progress and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T12:02:40.657722+00:00","company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","filing_date":"2026-09-01"}]}